Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.86 |
| ▸ | F10 | P00742 | 16/20 | 0.85 |
| ▸ | F2 | P00734 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181300 | 0.93 | KCNH2 (1.00) | KCNH2F10F2 | |
| SCHEMBL10179465 | 0.92 | F10 (1.00) | KCNH2F10F2 | |
| Betrixaban SCHEMBL158591 | 0.90 | F10 (1.00) | KCNH2F10F2 | |
| Betrixaban SCHEMBL29374026 | 0.90 | F10 (1.00) | KCNH2F10F2 | |
| Betrixaban SCHEMBL29858125 | 0.89 | F10 (0.98) | KCNH2F10F2 | |
| SCHEMBL15855106 | 0.86 | F10 (0.85) | KCNH2F10F2 | |
| SCHEMBL10177790 | 0.86 | F10 (1.00) | KCNH2F10F2 | |
| SCHEMBL15855154 | 0.86 | F10 (0.94) | KCNH2F10F2 | |
| SCHEMBL15855100 | 0.86 | F10 (0.86) | KCNH2F10F2 | |
| Betrixaban SCHEMBL20587589 | 0.85 | F10 (0.90) | KCNH2F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4744050-B2 | Benzamides And Related Inhibitors Of Factor Xa | — | 2011-08-10 | — | — | JP | claimed |
| EP-1216228-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001019788-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-6844367-B1 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-6835739-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040097561-A1 | For therapy of thrombosis | MILLENNIUM PHARMACEUTICALS, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20030162690-A1 | Bood anticoagulant | COR THERAPEUTICS, INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1259485-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1216228-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001064643-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001019788-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20040097561-A1 | For therapy of thrombosis | F2, F12, TFPI | KCNH2 1228/4885F10 21/4885F2 1/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | F2, F12, PLAT | KCNH2 1087/4885F10 14/4885F2 1/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20030162690-A1 | Bood anticoagulant | F2, SERPINC1, HABP2 | KCNH2 593/4885F10 18/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.